�Pfizer proclaimed that in patients with established centre disease, Lipitor� (atorvastatin ca) 80 mg not only significantly rock-bottom the congener risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg just also provided a sustained reduction in the endangerment of a subsequent second, third, fourth, and fifth cardiovascular result, according to a subanalysis of the five-year Treating to New Targets (TNT) study.
This subanalysis, designed and completed following the closure of the TNT study, was presented at the 2008 European Society of Cardiology Congress in Munich, Germany.
"The original TNT trial, as with most cardiovascular outcome trials, only evaluated the time to a patient's first-class honours degree cardiovascular upshot and therefore may not have in full accounted for the total clinical benefits achieved by intensive LDL-cholesterol lowering," aforementioned Dr. John LaRosa, president and professor of music at the State University of New York Downstate Medical Center in Brooklyn, New York, and a member of the TNT steering committee. "This subanalysis is of import because patients with heart disease often go on to suffer more than one cardiovascular event."
Any cardiovascular outcome, which was chosen as the termination for this post-hoc subanalysis, was defined as death from heart disease, nonfatal heart attack, resuscitated cardiac arrest, certain types of heart surgery, procedure-related heart attack, chest pain, fatal or nonfatal stroke, peripheral arterial disease or hospitalization due to chronic centre failure.
"These findings hint that patients can benefit from semipermanent therapy with high dosage Lipitor," continued Dr. LaRosa.
In this subanalysis of the TNT study, evaluating patients with established fondness disease (n=10,001), compared to Lipitor 10 mg, Lipitor 80 mg demonstrated:
- 19 percent significant relative peril reduction in a number one cardiovascular case (n=3,082);
- 21 percent significant congenator risk reduction in a subsequent sec cardiovascular event (n=1,516);
- 24 percent significant relation risk diminution in a subsequent third cardiovascular event (n=698);
- 28 percent significant relative hazard reduction in a subsequent fourth cardiovascular event (n=345);
- 29 pct significant congenator risk reduction in a subsequent fifth cardiovascular event (n=197).
"Although the original TNT study was non designed to look at subsequent cardiovascular events, these results ar compelling and suggestive of sustained welfare with Lipitor 80 mg compared with Lipitor 10 mg in patients with heart disease," said Dr. Rochelle Chaiken, vice president of the United States of Pfizer's global cardiovascular and metabolic medical team.
About the TNT Study
The TNT study was an investigator-led test coordinated by an independent steering commission and funded by Pfizer. The study enrolled 10,001 manpower and women with coronary heart disease aged 35 years to 75 age in 14 countries and followed them for an average of five long time. Primary study results were published in The New England Journal of Medicine in 2005.
The primary endpoint of the original TNT study was the occurrence of a first major cardiovascular event, outlined as death from middle disease, nonfatal heart attacks, resuscitated cardiac arrest, or fatal or non-fatal strokes.
In contrast, the termination for this subanalysis was any cardiovascular event, defined as death from fondness disease, nonfatal heart attack, resuscitated cardiac arrest, sealed types of heart surgical procedure, procedure-related heart attack, chest pain, fatal or nonfatal stroke, peripheral arterial disease or hospitalization due to chronic ticker failure.
Lipitor 80 mg is non a starting dose. Lipitor is not approved in all countries to abbreviate the peril of cardiovascular events in patients with existing warmheartedness disease.
Important U.S. Prescribing Information
Lipitor is a prescription medication. It is used in patients with multiple peril factors for heart disease such as family history, high blood pressure, age, low HDL ("good" cholesterin) or smoking to cut the jeopardy of a heart blast and fortuity, certain kinds of tenderness surgery and chest pain sensation.
Lipitor is also secondhand in patients with type 2 diabetes and at least one other danger factor for heart disease such as high stemma pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.
Lipitor is used in patients with existing coronary thrombosis heart disease to reduce the risk of mettle attack, slash, certain kinds of warmheartedness surgery, hospital care for warmheartedness failure, and chest nuisance.
When diet and exercise alone are not enough, Lipitor is used along with a low-fat dieting and exercise to lour cholesterol.
Lipitor is not for everyone. It is not for those with liver problems. And it is not for women who ar nursing, pregnant or may become meaning.
Patients pickings Lipitor should tell their doctors if they feel any new muscle pain or helplessness. This could be a sign of rare simply serious muscular tissue side effects. Patients should tell their doctors near all medications they take. This may help stave off serious do drugs interactions. Doctors should do blood tests to contain liver procedure before and during discussion and crataegus oxycantha adjust the dose. The most vernacular side personal effects are flatulency, constipation, stomach pain and heartburn. They tend to be mild and often go away.
http://www.Lipitor.com
More info
